Morisaki, Takashi et al. “NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.” Anticancer research vol. 34.8 (2014): 4529-38.;
Iliopoulou, Eleni G et al. “A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.” Cancer immunology, immunotherapy : CII vol. 59.12 (2010): 1781-9. doi:10.1007/s00262-010-0904-3;
Yoon, Jae Joon et al. “Cytotoxic activity and subset populations of peripheral blood natural killer cells in patients with chronic pain.” The Korean journal of pain vol. 31.1 (2018): 43-49. doi:10.3344/kjp.2018.31.1.43;
Baker, Darren J et al. “Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.” Nature vol. 530.7589 (2016): 184-9. doi:10.1038/nature16932;
Zú?iga, C.H., Acosta, B.I., Menchaca, R. et al. Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study. Alz Res Therapy 17. 40 (2025). https://doi.org/10.1186/s13195-025-01681-2;
Earls, Rachael H et al. “NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.” Proceedings of the National Academy of Sciences of the United States of America vol. 117.3 (2020): 1762-1771. doi:10.1073/pnas.1909110117;
Smith, Davey M et al. “Natural killer cells for antiviral therapy.” Science translational medicine vol. 15.677 (2023): eabl5278. doi:10.1126/scitranslmed.abl5278;
Schuster, Iona S et al. “Infection induces tissue-resident memory NK cells that safeguard tissue health.” Immunity vol. 56.3 (2023): 531-546.e6. doi:10.1016/j.immuni.2023.01.016